• 1
    Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997; 15: 10131021.
  • 2
    Pilepich MV, Winter K, Lawton C, et al. Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate. long-term results of Phase III RTOG study 85-31. Int J Radiat Oncol Biol Phys. 2003; 57(2 Suppl ): S172S173.
  • 3
    Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003; 21: 39723978.
  • 4
    Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997; 337: 295300.
  • 5
    Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial. Lancet. 2002; 360: 103106.
  • 6
    Pilepich MV, Winger K, Lawton C, et al. Phase III trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31 [abstract 1530]. Proc Am Soc Clin Oncol. 2003; 22: 381.
  • 7
    Krahn M, Ritvo P, Irvine J, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care. 2003; 41: 153164.
  • 8
    Hummel S, Paisley S, Morgan A, Currie E, Brewer N. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. Health Technol Assess. 2003; 7: iii, ix–x, 1–157.
  • 9
    Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA. 1993; 269: 26502658.
  • 10
    Sandler HM, Pajak TF, Hanks GE, Porter AT, Desilvio M, Shipley WU. Can biochemical failure (ASTRO definition) be used as a surrogate endpoint for prostate cancer survival in Phase III localized prostate cancer clinical trials? Analysis of RTOG Protocol 92-02 [abstract 1528]. Proc Am Soc Clin Oncol. 2003; 22: 381.
  • 11
    Owen JB, Grigsby PW, Caldwell TM, et al. Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the Radiation Therapy Oncology Group (RTOG) studies 90-03 and 91-04. Int J Radiat Oncol Biol Phys. 2001; 49: 633639.
  • 12
    Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: GoldM, SiegelJE, RussellLB, WeinsteinMC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 214235.
  • 13
    Piper NY, Kusada L, Lance R, Foley J, Moul J, Seay T. Adenocarcinoma of the prostate: an expensive way to die. Prostate Cancer Prostatic Dis. 2002; 5: 164166.
  • 14
    Bennett CL, Matchar D, McCrory D, McLeod DG, Crawford ED, Hillner BE. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer. 1996; 77: 18541861.
  • 15
    Saigal CS, Gornbein J, Nease R, Litwin MS. Predictors of utilities for health states in early stage prostate cancer. J Urol. 2001; 166: 942946.
  • 16
    Neymark N, Adriaenssen I, Gorlia T, Caleo S, Bolla M. Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ. 2002; 11: 233248.
  • 17
    Feigenberg SJ, Hanlon AL, Horwitz EM, Pollack A. Androgen deprivation increases late morbidity in prostate cancer patients treated with 3D conformal radiation therapy [abstract]. Int J Radiat Oncol Biol Phys. 2003; 57(2 Suppl ): S176.
  • 18
    Sanguineti G, Agostinelli S, Foppiano F, et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer. 2002; 86: 18431847.
  • 19
    Chon JK, Jacobs SC, Naslund MJ. The cost value of medical versus surgical hormonal therapy for metastatic prostate cancer. J Urol. 2000; 164(3 Pt 1): 735737.
  • 20
    Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol. 2001; 19: 7280.
  • 21
    Diamond TH, Bucci J, Kersley JH, Aslan P, Lynch WB, Bryant C. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. J Urol. 2004; 172: 529532.
  • 22
    Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004; 100: 892899.
  • 23
    Deng JH, Yang LP, Wang LS, Zhou DF. Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients. Asian J Androl. 2004; 6: 7577.